Horizon Pharma plc Announces the U.S. Patent and Trademark

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional Notices of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w

DUBLIN, IRELAND--(Marketwired - May 4, 2016) -  Horizon Pharma plc ( NASDAQ : HZNP ), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received three additional Notice of Allowances from the United States Patent and Trademark Office (USPTO) for U.S. patent application numbers 14/705,715 (U.S. publication number 2015-0320702), 14/804,793 (U.S. publication number 2015-0366830), and 14/810,129 (U.S. publication number 2015-0328174) entitled "Treatment of Pain with Topical Diclofenac" that covers Horizon's U.S. approved medicine PENNSAID ® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).

These Notices of Allowance conclude the substantive examination of the patent applications and will result in the issuance of U.S. patents after administrative processes are completed. The U.S. patents scheduled to issue from these applications will expire October 17, 2027. After issuance, Horizon plans to list the U.S. patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

About PENNSAID ® 2% PENNSAID (diclofenac sodium topical solution) 2% w/w is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis (OA) of the knee(s). PENNSAID 2% contains diclofenac sodium, an NSAID, and also includes dimethyl sulfoxide (DMSO), a powerful penetrating agent that helps ensure that diclofenac sodium is absorbed through the skin to the site of inflammation and pain. PENNSAID 2% is an alternative to oral NSAID treatment, reducing systemic exposure to a fraction of that provided by the oral NSAID diclofenac. The only topical NSAID offered with the convenience of a metered-dose pump, PENNSAID 2% is applied in two pumps, twice daily, to the site of OA knee pain. For more information, please see www.PENNSAID.com .

IMPORTANT SAFETY INFORMATION

WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK

Heart Risk

  • Non-steroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious heart clotting events, heart attack and stroke, which can kill you. This risk may increase with longer use. Patients with heart disease or risk factors for heart disease may be at greater risk.
  • PENNSAID 2% should not be used if you are in the hospital for certain heart surgeries.

Stomach and Intestine Risk

  • NSAIDs cause an increased risk of serious stomach and intestine events including bleeding, ulcers and holes in the stomach or intestines, which can kill you. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious stomach and intestine events.

CONTRAINDICATIONS

  • DO NOT USE PENNSAID 2% if you:
    • are in the hospital for certain heart surgeries.
    • know you are allergic to diclofenac sodium or any other ingredient of PENNSAID 2%.
    • have experienced asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, allergic reactions that will rarely kill you, to NSAIDs have been reported in such patients.

WARNINGS AND PRECAUTIONS

  • To minimize the potential for increased risk of serious heart events while being treated with an NSAID, use the lowest effective dose for the shortest duration possible.
  • Elevation of one or more liver tests may occur during therapy with NSAIDs. PENNSAID 2% should be discontinued immediately if abnormal liver tests persist or worsen.
  • Use with caution in patients with fluid retention or heart failure.
  • Hypertension can occur with NSAID treatment. Monitor blood pressure closely with PENNSAID 2% treatment.
  • Long-term use of NSAIDs can result in severe kidney injury. Use PENNSAID 2% with caution in patients at greatest risk of this reaction, including the elderly, those with impaired kidney function, heart failure, liver dysfunction and those taking diuretics and ACE-inhibitors (certain blood pressure medicines).
  • Severe allergic reactions may occur without prior use of PENNSAID 2%. NSAIDs can cause serious skin reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), which can kill you.
  • Wash and dry hands before and after use. Avoid contact of PENNSAID 2% with the eyes, nose and mouth.
  • PENNSAID 2% was not studied under the conditions of heat application, complete covering bandages or exercise; therefore, concurrent use of PENNSAID under these conditions is not recommended.
    • Do not:
    • Apply PENNSAID 2% to open wounds.
    • Wear clothing over the PENNSAID 2% treated knee until the treated knee is dry.
  • Shower for at least 30 minutes after applying PENNSAID 2%. 
  • Protect treated knee(s) from natural or artificial sunlight.
  • Protect treated knee(s) from sunlight (real and tanning booths).
  • Topicals, such as sunscreen and bug repellent, should not be used until after PENNSAID 2% treated knee(s) are completely dry.
  • Do not use with oral NSAIDs unless your doctor says it is OK and you have lab tests to check your progress.
  • There is no consistent evidence that regular use of aspirin lessens the increased risk of serious heart events, such as heart clotting, heart attack and stroke associated with NSAID use. As with all NSAIDs, regular administration of PENNSAID 2% and aspirin is not generally recommended because of the potential of increased risks.

ADVERSE REACTIONS

  • The most common adverse events in a phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness (22%), peeling (7%), redness (4%), itching (2%), pain (2%), skin hardening (2%), rash (2%) and scabbing ( < 1%). Other adverse reactions occurring in > 1% of patients receiving PENNSAID 2% included bladder infection (3%), bruising (2%), sinus congestion (2%) and nausea (2%).

USE IN SPECIFIC POPULATIONS

  • PENNSAID 2% should not be used in pregnant woman or in women who are breastfeeding and is not approved for use in children. 

For more information on PENNSAID 2%, please see the Medication Guide and Full Prescribing Information , available at www.PENNSAID.com .

About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, rheumatology and primary care business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com . Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the potential issuance of patents based on the Notices of Allowance from the U.S. Patent and Trademark Office, the expected terms of the patents, if issued, potential patent protection for PENNSAID 2% and plans to list any newly issued patents in the FDA's Orange Book. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether the administrative processes required for the issuance of these patents as indicated in the Notices of Allowance will be completed in a timely matter or at all, whether the patents, if issued as indicated in the Notices of Allowance, will provide sufficient protection and market exclusivity for PENNSAID 2%, whether any patents covering PENNSAID 2% may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations Investor-relations@horizonpharma.com Tina Ventura Vice President, Investor Relations Investor-relations@horizonpharma.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications media@horizonpharma.com Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 157

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 135

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 69

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 87

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 183

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading

Top 5 Most Recently Viewed Articles

GIGABYTE Unveils Compact NVIDIA GeForce RTX 50 Series GPUs

Updated Category News Views 348

GIGABYTE Shines at CES with Revolutionary Graphics Card Launch The latest unveiling from GIGABYTE, a leader in innovative computer hardware, features their NVIDIA GeForce RTX™ 50 Series graphics cards. These models, including the GeForce RTX™ 5090, RTX™ 5090 D, RTX™ 5080, RTX™ 5070 Ti, and RTX™ 5070, promise to elevate gaming and creative experiences...

Continue Reading
EssilorLuxottica's Strategic Share Buyback Announcement Details

Updated Category News Views 246

EssilorLuxottica: Share Buyback Update Disclosure of transactions in own shares EssilorLuxottica has recently informed the public about its share buyback activities, following the authorization from its Annual Shareholders’ Meeting held on April 30, 2024. This initiative reflects the company's commitment to maintaining a healthy and robust stock market presence. Recent...

Continue Reading
Aker BP Announces Ex-Dividend Payment of USD 0.63 Today

Updated Category News Views 185

Understanding Aker BP's Ex-Dividend Payment Aker BP ASA has officially announced that its shares will commence trading ex-dividend today, marking a significant moment for investors. The ex-dividend amount is set at USD 0.63 per share, equivalent to NOK 6.36193. This announcement is crucial for shareholders looking to understand their financial returns from this reputable...

Continue Reading
PL Developments Secures FDA Nod for Omeprazole and Debt Restructure

Updated Category News Views 331

PL Developments Reaches Major Milestones With FDA Approval PL Developments (PLD), a leader in the healthcare sector, recently announced two substantial achievements: the FDA's approval for its Omeprazole OTC ANDA and the successful refinancing of its corporate debt. These milestones mark significant advancements in the company's ongoing efforts to innovate and grow....

Continue Reading
Akari Therapeutics Gears Up for Innovations in ADC Payloads

Updated Category News Views 237

Akari Therapeutics Gears Up for Innovations in ADC Payloads Akari Therapeutics, Plc (NASDAQ: AKTX), is making strides in the oncology biotechnology field, particularly with its progressive advancements in antibody drug conjugates (ADCs). Recently, the company released an insightful segment of the CEO Corner, which provides a comprehensive update on its initiatives and...

Continue Reading